Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Acute cholecystitis (AC) is a very common complication of cholelithiasis, encountered in 20%
of symptomatic patients.
Nowadays laparoscopic cholecystectomy (LC) is the standard treatment in mild and moderates
forms of diseases and antibiotic therapy in the postoperatory of these patients remains under
discussion. However in the beginning, AC presents itself as an steril process, the
obstruction of the cystic duct initiates a cascade of inflammation, ischaemia and necrosis,
as well as bacterial proliferation within the gallbladder lumen. Bactibilia was a significant
factor associated with total, as well as infectious, operative complications. Regarding this,
for some authors, monotherapy with amoxicillin clavulanic (AMC) would be the best treatment
after LC in patients with mild and moderate cholecystitis without intraoperative
complications such as bile peritonitis, cholangitis, gallbladder perforation or abscess. In
the other hand, others do not prescribe antimicrobial treatment after surgery in these
selected patients.
There is controversy regarding the postoperative treatment with antibiotics in patients with
mild and moderate cholecystitis and all the evidence about this topic.
Therefore, investigators decided to conduct a prospective randomized study in patients
undergoing laparoscopic cholecystectomy for acute mild and moderate cholecystitis cancer. The
patients will be randomized to receive AMC or placebo after surgery. With this study
investigators intend to prove that are no clinical differences in postoperative outcomes
between patients treated with AMC and placebo.
The primary aim of the trial is to assess that there are no benefits in the use of
postoperative antibiotics in patients whit mild or moderate acute cholecystitis in whom a
laparoscopic cholecystectomy was performed.